<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02555358</url>
  </required_header>
  <id_info>
    <org_study_id>Alien Craft 0004</org_study_id>
    <nct_id>NCT02555358</nct_id>
  </id_info>
  <brief_title>Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study</brief_title>
  <official_title>Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Multicenter, Open, Randomized, Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qun Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the relationship of pCR rate and efficacy by comparing
      the two drugs and three drugs as neoadjuvant chemotherapy in advanced gastric cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be randomly assigned by a randomisation system in a 1:1:1 ratio to
      three group. The group A wil receive four cycles of DOX (docetaxel 60mg/m2 on day
      1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14,
      repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000
      mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as
      adjuvant therapy.The group B wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per
      day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant
      therapy and four cycles of Xelox as adjuvant therapy.The group C wil receive eight cycles of
      Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1,
      repeated every 3 weeks) as adjuvant therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The pathological complete response rate</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>Investigators graded all adverse events and toxic effects according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A（DOX）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B（Xelox）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C（Xelox）</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel,0xaliplatin,capecitabine</intervention_name>
    <description>docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d</description>
    <arm_group_label>A（DOX）</arm_group_label>
    <other_name>AISU,AIHENG,AIBIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin,capecitabine</intervention_name>
    <description>oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d</description>
    <arm_group_label>B（Xelox）</arm_group_label>
    <arm_group_label>C（Xelox）</arm_group_label>
    <other_name>AIHENG,AIBIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically proven in operable advanced gastric adenocarcinoma;

          2. Subjects who were identified as potentially resectable cases by a multidisciplinary
             consultation;

          3. KPS&gt; 80; ECOG score: 0-1;

          4. Expected survival&gt; 6 months;

          5. Age 20 -60;

          6. Major organ function has to meet the following criteria:

             Neutrophil count ≥1.5 × 109 / L, platelet count ≥100 × 109 / L, Hemoglobin ≥90g / L,
             liver function &lt;1.5 times the upper limit of normal, serum bilirubin ≤1.0 × UNL, serum
             creatinine &lt;1.5 × UNL, PT-INR / PTT &lt;1.7 times the upper limit of normal;

          7. Subjects has to voluntarily join the study and sign the Informed Consent Form for the
             study;

        Exclusion Criteria:

          1. Associated with serious diseases in liver ,kidney, cardiovascular system and other
             vital organs;

          2. History of hypersensitivity to docetaxel, capecitabine, oxaliplatin or the ingredients
             of this product;

          3. Receiving any form of chemotherapy or other study medication;

          4. Pregnancy or lactation women, or women with suspected pregnancy or men unless using a
             reliable and appropriate contraceptive method;

          5. Associated with inability to swallow, haemorrhagic peptic ulcer, mechanical or
             paralytic ileus, gastrointestinal active bleeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qun Zhao, director</last_name>
    <role>Study Chair</role>
    <affiliation>The 4th Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qun Zhao, director</last_name>
    <phone>13930162111</phone>
    <phone_ext>0311－86095588</phone_ext>
    <email>zhaoqun516@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan Tian</last_name>
    <phone>18531117658</phone>
    <phone_ext>0311－86095588</phone_ext>
    <email>tangy0767@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fourth Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qun Zhao, doctor</last_name>
      <phone>13930162111</phone>
      <email>zhaoqun516@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>1. Zhao Q, Li Y, Tan BB, Tian Y, Jiao ZK, Zhao XF, Zhang ZD, Wang D, Yang PG. XELOX neoadjuvant chemotherapy for advanced gastric cancer resection rate and the impact on prognosis. Journal of Cancer 2013,35 (10) : 773-777 2. Zhao Q, Li Y, Wang GY, Jiao ZK, Zhao XF, Zhang ZD, Tan BB, Zhou CX, Sun WL laparoscopic abdominal control study of gastric cancer resection surgery clinical effect. Chinese General Practice, 2013,16 (1B): 210-215. 3.Zhao Q, Li Y, Tian Y, Chen YN, Tan BB, Zhao XF, Jiao ZK, Zhang ZD, Chang SL. Histological Complete Response after Neoadjuvant XELOX in Advanced Gastric Carcinoma. Hepatogastroenterology. 2013 Jan 24;60(126)</citation>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2015</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Surgical director</investigator_title>
  </responsible_party>
  <keyword>Resectable advanced gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

